Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D2.545 - Perception of adult patients in an allergy clinic after using Scribe artificial intelligence, our experience
D2.546 - Ethical Impact of Generative AI in Clinical Practice for Asthma and Allergy
D2.547 - The Transparent and Credible AI for Clinical Protocols
D2.548 - Expert Evaluation of Dialogue Quality and Clinical Reasoning in a Hybrid Multilingual LLM–Algorithm Allergy Decision-Support System: A Pilot Study of 34 Real-World Cases
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
D3.455 - Comparative Characterization of Olfactory Dysfunction in Mouse Models of Eosinophilic Chronic Rhinosinusitis
D3.456 - BEAMER: A multidisciplinary model for disease-agnostic adherence integrating chronic rhinosinusitis: development and prospective study
D3.451 - Long-term follow-up of ASA therapy after desensitization in patients with chronic rhinosinusitis with nasal polyps indicates high rate of treatment discontinuation
D3.454 - Do we still need aspirin desensitization therapy for nasal polyposis?
D3.457 - Does the Way We Ask Matter? Comparing Self- and Interviewer-Administered RQLQ in Allergic Rhinoconjunctivitis
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download